Processa Pharmaceuticals Statistics
Share Statistics
Processa Pharmaceuticals has 3.70M shares outstanding. The number of shares has increased by 116.56% in one year.
| Shares Outstanding | 3.70M |
| Shares Change (YoY) | n/a |
| Shares Change (QoQ) | 13.55% |
| Owned by Institutions (%) | n/a |
| Shares Floating | 3.28M |
| Failed to Deliver (FTD) Shares | 5.41K |
| FTD / Avg. Volume | 1.65% |
Short Selling Information
The latest short interest is 333.24K, so 9.01% of the outstanding shares have been sold short.
| Short Interest | 333.24K |
| Short % of Shares Out | 9.01% |
| Short % of Float | 10.16% |
| Short Ratio (days to cover) | 0.4 |
Valuation Ratios
The PE ratio is -0.79 and the forward PE ratio is -0.5.
| PE Ratio | -0.79 |
| Forward PE | -0.5 |
| PS Ratio | 0 |
| Forward PS | 0.1 |
| PB Ratio | 1.76 |
| P/FCF Ratio | -1.09 |
| PEG Ratio | n/a |
Enterprise Valuation
Currently the Enterprise Value (EV) is not available for Processa Pharmaceuticals Inc..
| EV / Earnings | n/a |
| EV / Sales | n/a |
| EV / EBITDA | n/a |
| EV / EBIT | n/a |
| EV / FCF | n/a |
Financial Position
The company has a current ratio of 7.71, with a Debt / Equity ratio of 0.
| Current Ratio | 7.71 |
| Quick Ratio | 7.71 |
| Debt / Equity | 0 |
| Total Debt / Capitalization | 0 |
| Cash Flow / Debt | 0 |
| Interest Coverage | 0 |
Financial Efficiency
Return on equity (ROE) is -2.23% and return on capital (ROIC) is -222.91%.
| Return on Equity (ROE) | -2.23% |
| Return on Assets (ROA) | -1.92% |
| Return on Capital (ROIC) | -222.91% |
| Revenue Per Employee | 0 |
| Profits Per Employee | -855.50K |
| Employee Count | 13 |
| Asset Turnover | 0 |
| Inventory Turnover | 0 |
Taxes
| Income Tax | 0 |
| Effective Tax Rate | 0 |
Stock Price Statistics
The stock price has increased by -84.07% in the last 52 weeks. The beta is 0.6, so Processa Pharmaceuticals 's price volatility has been higher than the market average.
| Beta | 0.6 |
| 52-Week Price Change | -84.07% |
| 50-Day Moving Average | 1.07 |
| 200-Day Moving Average | 1.57 |
| Relative Strength Index (RSI) | 48.65 |
| Average Volume (20 Days) | 328.36K |
Income Statement
| Revenue | n/a |
| Gross Profit | -222 |
| Operating Income | -11.46M |
| Net Income | -11.12M |
| EBITDA | -11.46M |
| EBIT | n/a |
| Earnings Per Share (EPS) | -8.48 |
Balance Sheet
The company has 4.71M in cash and 150.55K in debt, giving a net cash position of 4.56M.
| Cash & Cash Equivalents | 4.71M |
| Total Debt | 150.55K |
| Net Cash | 4.56M |
| Retained Earnings | -75.37M |
| Total Assets | 4.94M |
| Working Capital | 3.62M |
Cash Flow
In the last 12 months, operating cash flow was -8.06M and capital expenditures -2.78K, giving a free cash flow of -8.07M.
| Operating Cash Flow | -8.06M |
| Capital Expenditures | -2.78K |
| Free Cash Flow | -8.07M |
| FCF Per Share | -6.15 |
Margins
| Gross Margin | n/a |
| Operating Margin | n/a |
| Pretax Margin | n/a |
| Profit Margin | n/a |
| EBITDA Margin | n/a |
| EBIT Margin | n/a |
| FCF Margin | n/a |
Dividends & Yields
PCSA does not appear to pay any dividends at this time.
| Dividend Per Share | n/a |
| Dividend Yield | n/a |
| Dividend Growth (YoY) | n/a |
| Payout Ratio | n/a |
| Earnings Yield | -839.6% |
| FCF Yield | -215.98% |
Analyst Forecast
The average price target for PCSA is $5, which is 395% higher than the current price. The consensus rating is "Buy".
| Price Target | $5 |
| Price Target Difference | 395% |
| Analyst Consensus | Buy |
| Analyst Count | 2 |
Stock Splits
The last stock split was on Jan 22, 2024. It was a backward split with a ratio of 1:20.
| Last Split Date | Jan 22, 2024 |
| Split Type | backward |
| Split Ratio | 1:20 |
Scores
| Altman Z-Score | -29.53 |
| Piotroski F-Score | 1 |